Wall Street analysts predict that Allogene Therapeutics Inc (NASDAQ:ALLO) will report earnings of ($0.40) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Allogene Therapeutics’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.43). The company is scheduled to issue its next quarterly earnings report before the market opens on Tuesday, May 7th.
On average, analysts expect that Allogene Therapeutics will report full-year earnings of ($2.13) per share for the current fiscal year, with EPS estimates ranging from ($2.50) to ($2.04). For the next fiscal year, analysts expect that the company will report earnings of ($2.56) per share, with EPS estimates ranging from ($2.93) to ($2.20). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Allogene Therapeutics.
Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Friday, March 8th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10).
Several hedge funds have recently modified their holdings of ALLO. Strs Ohio bought a new position in shares of Allogene Therapeutics during the fourth quarter worth about $156,000. Rhumbline Advisers bought a new position in Allogene Therapeutics in the fourth quarter worth about $829,000. Creative Planning bought a new position in Allogene Therapeutics in the fourth quarter worth about $544,000. Shikiar Asset Management Inc. bought a new position in Allogene Therapeutics in the fourth quarter worth about $1,056,000. Finally, TD Asset Management Inc. bought a new position in Allogene Therapeutics in the fourth quarter worth about $674,000. 51.60% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:ALLO opened at $30.07 on Friday. The stock has a market capitalization of $3.57 billion and a price-to-earnings ratio of -4.57. Allogene Therapeutics has a 1-year low of $21.67 and a 1-year high of $35.55.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Read More: What is the balance sheet?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.